Volume 13, Number 6—June 2007
Research
Minority-Variant pfcrt K76T Mutations and Chloroquine Resistance, Malawi
Jonathan J. Juliano*, Jesse J. Kwiek*, Kathryn Cappell*, Victor Mwapasa†, and Steven R Meshnick*
Table 1
Characteristics of patient samples*
| Characteristic | Value (range) |
|---|---|
| Age (y) | |
| Total | 21.9 (15–35) |
| MHP patients | 23.7 (17–31) |
| MM patients | 21.2 (15–35) |
| Parasite density (no. parasites/200 leukocytes) | |
| Total | 243.6 (4–2,202) |
| MHP patients | 599.7 (4–2,202) |
| MM patients | 83.3 (5–750) |
| Gravidity | |
| Total | 2.26 (1–9) |
| MHP patients | 2.37 (1–3) |
| MM patients | 2.21 (1–9) |
| Anemia (hemoglobin <11 g/dL) | |
| Total | 64/87 (73.6%) |
| MHP patients | 21/27 (77.8%) |
| MM patients | 43/60 (71.7%) |
| HIV status | |
| Total† | 38/58 (65.5%) |
| MHP patients | 27/27 (100%) |
| MM patients | 11/31 (35.5%) |
| Clinical symptoms‡ | |
| Fever | 14/27 (51.8%) |
| Headache | 18/27 (66.7%) |
| General body pain | 13/27 (48.1%) |
| Preventive measures‡ | |
| Bed net use§ | 6/19 (31.6%) |
*MHP, Malaria and HIV in Pregnancy; MM, Mpemba and Madziabango.
†29 patients declined testing.
‡Data only available for MHP patients.
§No data available for 8 patients.
Page created: May 31, 2011
Page updated: May 31, 2011
Page reviewed: May 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.